HESylation - Results
Fresenius Kabi is applying the HESylation technology to various (biopharmaceutical) drugs. Due to our confidentiality obligations to potential partners we cannot share much of the generated data. However, some results of our proprietary HESylation technology are given below.
In a pharmacodynamic study in mice HESylated EPO was able to increase the area under the curve (AUC) (change of hematocrit) more than fourfold versus the same dose of EPO. Furthermore, the AUC of HESylated EPO was more than one and a half times higher than the same dose of (marketed) Aranesp®. For details please click here to enlarge the figure.
In a pharmacodynamic study in rats HESylated G-CSF was able to increase the AUC (white blood cell count) more than fourfold versus the same dose of marketed Neupogen®. The AUC was similar to the same dose of marketed Neulasta®. For details please click here to enlarge the figure.
Fresenius Kabi has also applied the HESylation technology to many other proteins, including Interferon alpha with very promising results.